Securities Code: 4506
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2021
I. | Consolidated Financial Highlights | 1 |
II. | Consolidated Statement of Profit or Loss | 3 |
III. | Segment Information | 4 |
IV. | Revenues Information | 5 |
- Consolidated Statement of Financial Position 7
VI. | Changes in Quarterly Results | 8 |
VII. | Major Consolidated Subsidiaries | 8 |
VIII. | Shareholder Positioning | 9 |
IX. | Development Pipeline | 10 |
- Profiles of Major Products under Development 14
May 12, 2021
Sumitomo Dainippon Pharma Co., Ltd.
- This material contains forecasts, projections, targets, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties. Accordingly, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.
- All values are rounded. Therefore totals may not be consistent with aggregated figures.
I. Consolidated Financial Highlights
1. Consolidated Statement of Profit or Loss (Core Basis) | (Billions of yen) | ||||||||
FY2019 | FY2020 | Change | FY2021 | Change | |||||
% YoY | (Forecast) | % YoY | |||||||
Revenue | 482.8 | 516.0 | 6.9 | 578.0 | 12.0 | ||||
Cost of sales *1 | 128.3 | 137.5 | 7.1 | 156.0 | 13.5 | ||||
Gross profit | 354.4 | 378.5 | 6.8 | 422.0 | 11.5 | ||||
SG&A expenses *1 | 190.0 | 211.8 | 11.5 | 263.0 | 24.2 | ||||
R&D expenses *1 | 92.6 | 97.1 | 4.8 | 95.0 | (2.1) | ||||
Other operating income/expenses *2 | 0.2 | (0.0) | - | ||||||
Core operating profit | 72.0 | 69.6 | (3.3) | 64.0 | (8.0) | ||||
Changes in fair value of contingent | 48.5 | 22.5 | (1.0) | ||||||
consideration (negative number indicates loss) | |||||||||
Other non-recurring items *3 | (37.2) | (20.8) | (2.0) | ||||||
(negative number indicates loss) | |||||||||
Operating profit | 83.2 | 71.2 | (14.4) | 61.0 | (14.4) | ||||
Net profit | 35.9 | 36.8 | 2.5 | N/A | |||||
Net profit attributable to owners of the parent | 40.8 | 56.2 | 38.0 | 41.0 | (27.1) | ||||
Basic earnings per share (yen) | 102.58 | 141.50 | 103.20 | ||||||
Net profit/ Equity attributable to owners of the | 7.9% | 10.1% | 6.9% | ||||||
parent (ROE) | |||||||||
3.3% | 3.1% | N/A | |||||||
Return on invested capital (ROIC) | |||||||||
Payout ratio | 27.3% | 19.8% | 27.1% | ||||||
*1 | Exclude non-recurring items (impairment | ||||||||
2. Consolidated Statement of Profit | (Billions of yen) | loss, changes in fair value of contingent | |||||||
or Loss (Full Basis) | consideration, etc.) | ||||||||
*2 "share of P/L of associates accounted for | |||||||||
Change | |||||||||
FY2019 | FY2020 | using equity method" | |||||||
% YoY | *3 | ||||||||
Non-recurring items ("other operating | |||||||||
Revenue | 482.7 | 516.0 | 6.9 | income and expenses" except for *2 | |||||
items, impairment loss, etc.) | |||||||||
Cost of sales | 129.7 | 137.8 | 6.2 | ||||||
Gross profit | 353.1 | 378.2 | 7.1 | ||||||
SG&A expenses | 154.3 | 190.4 | 23.3 | ||||||
R&D expenses | 115.1 | 132.7 | 15.3 | ||||||
Other operating income/expenses | (0.4) | 16.1 | |||||||
Operating profit | 83.2 | 71.2 | (14.4) | ||||||
Finance income/costs | 0.7 | 6.6 | |||||||
Profit before taxes | 83.9 | 77.9 | (7.3) | ||||||
Income tax expenses | 48.0 | 41.0 | |||||||
Net profit | 35.9 | 36.8 | 2.5 | ||||||
Net profit attributable to owners of the parent | 40.8 | 56.2 | 38.0 | ||||||
3. Consolidated Statement of | |||||||||
FY2019 | FY2020 | (Billions of yen) | |||||||
Cash Flows | |||||||||
Net cash provided by operating activities | 46.1 | 135.6 | |||||||
Net cash provided by (used in) investing activities | (312.7) | 8.9 | |||||||
Net cash provided by (used in) financing activities | 231.1 | (57.2) | |||||||
Cash and cash equivalents at the end of period | 101.7 | 193.7 |
4. Foreign Exchange Rates | FY2019 | FY2020 | FY2021 | ||
assumption | |||||
Average | |||||
Period end | Average | Period end | Average | ||
rate | rate | rate | rate | rate | |
Yen / USD | 108.8 | 108.7 | 110.7 | 106.1 | 110.0 |
Yen / RMB | 15.3 | 15.6 | 16.9 | 15.7 | 16.5 |
Forex sensitivity FY2021
(Impact of yen
depreciation by ¥1)
Core operating
Revenue profit
3.2 (0.2)
1.8 0.5
(Billions of yen)
―supplementary1―
5. Capital Expenditures/ | FY2019 | FY2020 | Change | FY2021 | Change | |
Depreciation and Amortization | (Forecast) | (Billions of yen) | ||||
Capital expenditures | 12.0 | 12.7 | 0.7 | 12.0 | (0.7) | |
Depreciation of | 10.5 | 10.6 | 0.1 | 10.1 | (0.5) | |
Property, plant and equipment | ||||||
Amortization of Intangible assets | 6.9 | 12.0 | 5.2 | 33.9 | 21.9 | |
Related to products (patent rights/ | 4.4 | 9.6 | 5.1 | 31.2 | 21.6 | |
marketing rights) included in above | ||||||
Note: The amount of capital expenditures are for tangible fixed assets and software.
Major capital expenditure project in FY2021 (continued)
Reinforcement of production facilities, total budget ¥2.0billion, to be completed in FY2022
Establishment of manufacturing facility for regenerative medicine and cell therapy, total budget ¥1.1billion, to be completed in FY2021
―supplementary2―
II. Consolidated Statement of Profit or Loss
1. Consolidated Statement of Profit or Loss (Core Basis) | (Billions of yen) | |||||
FY2019 | FY2020 | Change | Change | |||
% | ||||||
Revenue | 482.8 | 516.0 | 33.2 | 6.9 | ||
Overseas revenue | 307.8 | 327.3 | 19.5 | 6.3 | ||
% of Revenue | 63.8% | 63.4% | ||||
Cost of sales | 128.3 | 137.5 | 9.1 | 7.1 | ||
% of Revenue | 26.6% | 26.6% | ||||
Gross profit | 354.4 | 378.5 | 24.0 | 6.8 | ||
SG&A expenses | 190.0 | 211.8 | 21.8 | 11.5 | ||
Labor costs | 80.7 | 100.1 | 19.4 | 24.0 | ||
Advertising and promotion costs | 22.7 | 19.6 | (3.1) | (13.8) | ||
Sales promotion costs | 15.1 | 17.8 | 2.7 | 18.2 | ||
Amortization/Depreciation | 11.3 | 16.7 | 5.4 | 48.2 | ||
Others | 60.2 | 57.6 | (2.6) | (4.4) | ||
R&D expenses | 92.6 | 97.1 | 4.5 | 4.8 | ||
% of Revenue | 19.2% | 18.8% | ||||
Other operating income/expenses | 0.2 | (0.0) | (0.2) | |||
Core operating profit | 72.0 | 69.6 | (2.4) | (3.3) | ||
Changes in fair value of contingent | 48.5 | 22.5 | (26.0) | |||
consideration * | ||||||
Other non-recurring items * | (37.2) | (20.8) | 16.4 | |||
Operating profit | 83.2 | 71.2 | (12.0) | (14.4) | ||
Finance income | 3.6 | 9.2 | 5.6 | |||
Finance costs | 2.9 | 2.6 | (0.3) | |||
Profit before taxes | 83.9 | 77.9 | (6.1) | (7.3) | ||
Income tax expenses | 48.0 | 41.0 | (7.0) | |||
Net profit | 35.9 | 36.8 | 0.9 | 2.5 | ||
Net profit attributable to owners | 40.8 | 56.2 | 15.5 | 38.0 | ||
of the parent | ||||||
* Negative number indicates loss.
billion | Change | FX rate |
Japan | 12.8 | |
North America | 19.2 | (6.9) |
China | (0.8) | 0.1 |
Other Regions | 2.4 | |
Other | (0.5) |
・Include Sumitovant +39.9
・Include Sumitovant +22.2
・Include Sumitovant 15.5
Changes in fair value of contingent | ||
consideration | FY19 | FY20 |
LONHALA®MAGNAIR® | *8.7 | - |
former BBI | *26.2 | *17.0 |
former Tolero | *13.6 | *5.5 |
- Decrease in fair value by review of business plan (cost reversal)
・FY19: Impairment loss of IPR&D FY20: Gain on sale of fixed assets and
impairment loss of IPR&D
・FY19: Reversal of deferred tax assets in U.S.
2. Adjustments to Core Operating Profit
(Billions of yen) | |||||||
FY2020 Results | Full Basis | Core Basis | Adjustment | Major adjustment items | |||
Revenue | 516.0 | 516.0 | - | ||||
Cost of sales | 137.8 | 137.5 | (0.3) | ||||
Gross profit | 378.2 | 378.5 | 0.3 | ||||
SG&A expenses | 190.4 | 211.8 | 21.4 | Changes in fair value of contingent consideration 22.5 | |||
Business structure improvement expenses (0.9) | |||||||
R&D expenses | 132.7 | 97.1 | (35.6) | Impaiment losses (35.4) | |||
Other operating income | 17.7 | (0.0) | (17.7) | Gain on sale of former Ibaraki plant (16.7) | |||
Other operating expenses | 1.6 | ‐ | (1.6) | ||||
Operating profit | 71.2 | 69.6 | (1.6) |
―supplementary3―
III. Segment Information (Core Basis)
(Billions of yen) | |||||||
FY2020 Results | Pharmaceuticals Business | Other | Total | ||||
North | Other | ||||||
Japan | China | Subtotal | Business | ||||
America | Regions | ||||||
Revenue (Sales to customers) | 152.5 | 281.5 | 27.8 | 17.2 | 479.1 | 36.9 | 516.0 |
Cost of sales | 77.5 | 20.8 | 5.4 | 5.7 | 109.4 | 28.1 | 137.5 |
Gross profit | 75.1 | 260.7 | 22.5 | 11.5 | 369.8 | 8.7 | 378.5 |
SG&A expenses | 50.8 | 143.8 | 9.2 | 2.8 | 206.7 | 5.1 | 211.8 |
Core segment profit | 24.3 | 116.9 | 13.2 | 8.7 | 163.1 | 3.6 | 166.7 |
R&D expenses *1 | 96.2 | 0.9 | 97.1 | ||||
Other operating income/expenses | (0.0) | (0.0) | (0.0) | ||||
(Core basis)*2 | |||||||
Core operating profit | 66.9 | 2.7 | 69.6 | ||||
(Billions of yen) | |||||||
FY2021 Forecasts | Pharmaceuticals Business | Other | |||||
North | Other | Total | |||||
Japan | China | Subtotal | Business | ||||
America | Regions | ||||||
Revenue (Sales to customers) | 150.0 | 349.7 | 29.8 | 10.3 | 539.8 | 38.2 | 578.0 |
Cost of sales | 78.1 | 38.5 | 5.5 | 4.6 | 126.7 | 29.3 | 156.0 |
Gross profit | 71.9 | 311.2 | 24.3 | 5.7 | 413.1 | 8.9 | 422.0 |
SG&A expenses | 52.9 | 191.9 | 10.9 | 1.6 | 257.3 | 5.7 | 263.0 |
Core segment profit | 19.0 | 119.3 | 13.4 | 4.1 | 155.8 | 3.2 | 159.0 |
R&D expenses *1 | 94.0 | 1.0 | 95.0 | ||||
Other operating income/expenses | - | - | - | ||||
(Core basis)*2 | |||||||
Core operating profit | 61.8 | 2.2 | 64.0 | ||||
(Billions of yen) | |||||||
(Ref.) FY2019 Results | Pharmaceuticals Business | Other | |||||
North | Other | Total | |||||
Japan | China | Subtotal | Business | ||||
America | Regions | ||||||
Revenue (Sales to customers) | 139.7 | 262.3 | 28.6 | 14.8 | 445.4 | 37.4 | 482.8 |
Cost of sales | 65.0 | 24.0 | 5.4 | 5.0 | 99.5 | 28.9 | 128.3 |
Gross profit | 74.7 | 238.3 | 23.2 | 9.8 | 346.0 | 8.4 | 354.4 |
SG&A expenses | 51.8 | 120.8 | 8.8 | 3.4 | 184.8 | 5.2 | 190.0 |
Core segment profit | 22.9 | 117.5 | 14.4 | 6.4 | 161.2 | 3.2 | 164.4 |
R&D expenses *1 | 91.7 | 0.9 | 92.6 | ||||
Other operating income/expenses | 0.1 | 0.0 | 0.2 | ||||
(Core basis)*2 | |||||||
Core operating profit | 69.7 | 2.3 | 72.0 |
*1 R&D expenses for pharmaceuticals business are controlled globally and not allocated to each segment. *2 P/L of associates accounted for using equity method
―supplementary4―
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Sumitomo Dainippon Pharma Co. Ltd. published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2021 12:59:05 UTC.